{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T16:22:22Z","timestamp":1792513342333,"version":"4.5.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T00:00:00Z","timestamp":1761609600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T00:00:00Z","timestamp":1761609600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Cell Pediatr"],"DOI":"10.1186\/s40348-025-00202-3","type":"journal-article","created":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T13:51:19Z","timestamp":1761659479000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Achondroplasia treatments in children aged 5 and older"],"prefix":"10.1186","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-0748-3062","authenticated-orcid":false,"given":"Emmanuelle","family":"Zakheim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonal","family":"Sachdeva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9705-1247","authenticated-orcid":false,"given":"Daniel","family":"Moon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel Nicole","family":"Ortiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nishant","family":"Mistry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Floyd","family":"Culler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,28]]},"reference":[{"issue":"1","key":"202_CR1","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1056\/NEJMoa1813446","volume":"381","author":"R Savarirayan","year":"2019","unstructured":"Savarirayan R, Irving M, Bacino CA, Bostwick B, Charrow J, Cormier-Daire V, Le Quan Sang KH, Dickson P, Harmatz P, Phillips J, Owen N, Cherukuri A, Jayaram K, Jeha GS, Larimore K, Chan ML, Labed AH, Day J, Hoover-fong J (2019) C-type natriuretic peptide analogue therapy in children with achondroplasia. N Engl J Med 381(1):25\u201335. https:\/\/doi.org\/10.1056\/NEJMoa1813446","journal-title":"N Engl J Med"},{"key":"202_CR2","doi-asserted-by":"publisher","unstructured":"Baujat G, Legeai-Mallet L, Finidori G, Cormier-Daire V, Le Merrer M, Achondroplasia (2008) Best Pract Res Clin Rheumatol. ;22(1):3\u201318. https:\/\/doi.org\/10.1016\/j.berh.2007.12.008. PMID: 18328977","DOI":"10.1016\/j.berh.2007.12.008"},{"key":"202_CR3","unstructured":"Legare JM (2023) Achondroplasia. In: Adam MP, Feldman J, Mirzaa GM, Pagon RA, Wallace SE, Amemiya A, eds. GeneReviews\u00ae. Seattle (WA): University of Washington, Seattle; 1993\u20132025. Updated May 11, PMID: 20301331"},{"issue":"6","key":"202_CR4","doi-asserted-by":"publisher","first-page":"1764","DOI":"10.1093\/hmg\/ddu594","volume":"24","author":"ZQ Zhou","year":"2015","unstructured":"Zhou ZQ, Ota S, Deng C, Akiyama H, Hurlin PJ (2015) Mutant activated FGFR3 impairs endochondral bone growth by preventing SOX9 downregulation in differentiating chondrocytes. Hum Mol Genet 24(6):1764\u20131773. https:\/\/doi.org\/10.1093\/hmg\/ddu594Epub 2014 Nov 28. PMID: 25432534; PMCID: PMC4351382","journal-title":"Hum Mol Genet"},{"issue":"6","key":"202_CR5","doi-asserted-by":"publisher","first-page":"e20201010","DOI":"10.1542\/peds.2020-1010","volume":"145","author":"JH-FCI Scott","year":"2020","unstructured":"Scott JH-FCI, Jones MC, Committee on genetics, Chen E, Trotter TL, Berry SA, Leah W, Burke TA, Geleske R, Hamid RJ, Hopkin WJ, Introne MJ, Lyons (2020) Angela Scheuerle, Joan M. Stoler; health supervision for people with achondroplasia. Pediatr June 145(6):e20201010. https:\/\/doi.org\/10.1542\/peds.2020-1010","journal-title":"Pediatr June"},{"key":"202_CR6","doi-asserted-by":"publisher","unstructured":"Hoover-Fong J, Cheung MS, Fano V, Hagenas L, Hecht JT, Ireland P, Irving M, Mohnike K, Offiah AC, Okenfuss E, Ozono K, Raggio C, Tofts L, Kelly D, Shediac R, Pan W, Savarirayan R (2021) Lifetime impact of achondroplasia: Current evidence and perspectives on the natural history. Bone. ;146:115872. https:\/\/doi.org\/10.1016\/j.bone.2021.115872. Epub 2021 Feb 3. PMID: 33545406","DOI":"10.1016\/j.bone.2021.115872"},{"issue":"11","key":"202_CR7","doi-asserted-by":"publisher","first-page":"2540","DOI":"10.1002\/ajmg.a.61825","volume":"182","author":"E Okenfuss","year":"2020","unstructured":"Okenfuss E, Moghaddam B, Avins AL (2020) Natural history of achondroplasia: A retrospective review of longitudinal clinical data. Am J Med Genet A 182(11):2540\u20132551. https:\/\/doi.org\/10.1002\/ajmg.a.61825Epub 2020 Aug 31. PMID: 32864841","journal-title":"Am J Med Genet A"},{"key":"202_CR8","unstructured":"U.S. Food and Drug Administration. FDA approves first drug to improve growth in children with most common form of dwarfism. Published November 19, (2021) Accessed July 7, 2025. https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-drug-improve-growth-children-most-common-form-dwarfism"},{"key":"202_CR9","unstructured":"Therapeutics QED (2025) Inc. Phase 2, open-label, dose-escalation and dose-expansion study of Infigratinib in children with achondroplasia (PROPEL 2) (NCT04265651). ClinicalTrials.gov. Published March 10, 2020. Accessed July 7. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04265651"},{"key":"202_CR10","unstructured":"Ascendis Pharma AS (2025), June 2 FDA accepts TransCon\u00ae CNP NDA for priority review [Press release]. In Investors \u2013 News Releases. Retrieved September 3, 2025, from https:\/\/investors.ascendispharma.com\/news-releases\/news-release-details\/fda-accepts-transconr-cnp-nda-priority-review"},{"issue":"9\u201310","key":"202_CR11","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1159\/000520812","volume":"94","author":"DB Allen","year":"2021","unstructured":"Allen DB, Merchant N, Miller BS, Backeljauw PF (2021) Evolution and future of growth plate therapeutics. Horm Res Paediatr 94(9\u201310):319\u2013332. https:\/\/doi.org\/10.1159\/000520812","journal-title":"Horm Res Paediatr"},{"issue":"3","key":"202_CR12","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1124\/jpet.119.258251","volume":"370","author":"VM Breinholt","year":"2019","unstructured":"Breinholt VM, Rasmussen CE, Mygind PH, Kjelgaard-Hansen M, Faltinger F, Bernhard A, Zettler J, Hersel U (2019) TransCon CNP, a Sustained-Release C-Type natriuretic peptide Prodrug, a potentially safe and efficacious new therapeutic modality for the treatment of comorbidities associated with fibroblast growth factor receptor 3-Related skeletal dysplasias. J Pharmacol Exp Ther 370(3):459\u2013471. https:\/\/doi.org\/10.1124\/jpet.119.258251Epub 2019 Jun 24. PMID: 31235532","journal-title":"J Pharmacol Exp Ther"},{"issue":"16","key":"202_CR13","doi-asserted-by":"publisher","first-page":"6211","DOI":"10.1073\/pnas.1117147109","volume":"109","author":"DV Santi","year":"2012","unstructured":"Santi DV, Schneider EL, Reid R, Robinson L, Ashley GW (2012) Predictable and tunable half-life extension of therapeutic agents by controlled chemical release from macromolecular conjugates. Proc Natl Acad Sci U S A 109(16):6211\u20136216. https:\/\/doi.org\/10.1073\/pnas.1117147109Epub 2012 Apr 2. PMID: 22474378; PMCID: PMC3341049","journal-title":"Proc Natl Acad Sci U S A"},{"key":"202_CR14","unstructured":"BioMarin Pharmaceutical Inc (2016) A study to evaluate the efficacy and safety of BMN-111 in children with achondroplasia (NCT03197766). ClinicalTrials Gov Published Dec 12, https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03197766"},{"key":"202_CR15","unstructured":"ClinicalTrials.gov. (n.d.). A dose escalation trial evaluating safety\u2026 NCT04085523).Retrieved September 3, 2025, from https:\/\/www.clinicaltrials.gov\/study\/NCT04085523?tab=results"},{"issue":"7","key":"202_CR16","doi-asserted-by":"publisher","first-page":"e2309","DOI":"10.1210\/clinem\/dgaf017","volume":"110","author":"N Merchant","year":"2025","unstructured":"Merchant N, Hoover-Fong J, Carroll RS (2025) Approach to the patient with Achondroplasia-New considerations for Diagnosis, Management, and treatment. J Clin Endocrinol Metab 110(7):e2309\u2013e2316. https:\/\/doi.org\/10.1210\/clinem\/dgaf017","journal-title":"J Clin Endocrinol Metab"},{"key":"202_CR17","doi-asserted-by":"publisher","unstructured":"Savarirayan R, Irving M, Harmatz P, Delgado B, Wilcox WR, Philips JH, Owen NJ, Bacino CA, Tofts L, Charrow J, Polgreen LE, Hoover-Fong J, Arundel P, Ginebreda I, Saal HM, Basel D (2022) Growth parameters in children with achondroplasia: A 7-year, prospective, multinational, observational study. 24(12):2444\u20132452 Rosendo Ullot Font, Keiichi Ozono, Bober, M. B., & Val\u00e9rie Cormier-Daire. https:\/\/doi.org\/10.1016\/j.gim.2022.08.015","DOI":"10.1016\/j.gim.2022.08.015"},{"issue":"6","key":"202_CR18","doi-asserted-by":"publisher","first-page":"2104","DOI":"10.1210\/jc.2013-4455","volume":"99","author":"A Kelly","year":"2014","unstructured":"Kelly A, Winer KK, Kalkwarf H, Oberfield SE, Lappe J, Gilsanz V, Zemel BS (2014) Age-based reference ranges for annual height velocity in US children. J Clin Endocrinol Metab 99(6):2104\u20132112. https:\/\/doi.org\/10.1210\/jc.2013-4455","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"202_CR19","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1177\/12034754231188444","volume":"27","author":"PJ Kim","year":"2023","unstructured":"Kim PJ, Lansang RP, Vender R (2023) A systematic review and meta-analysis of injection site reactions in randomized-controlled trials of biologic injections. J Cutan Med Surg 27(4):358\u2013367. https:\/\/doi.org\/10.1177\/12034754231188444","journal-title":"J Cutan Med Surg"},{"issue":"12","key":"202_CR20","doi-asserted-by":"publisher","first-page":"982","DOI":"10.3109\/09638288.2011.631677","volume":"34","author":"F Schiedel","year":"2012","unstructured":"Schiedel F, R\u00f6dl R (2012) Lower limb lengthening in patients with disproportionate short stature with achondroplasia: a systematic review of the last 20 years. Disabil Rehabil 34(12):982\u2013987. https:\/\/doi.org\/10.3109\/09638288.2011.631677Epub 2011 Nov 23. PMID: 22112021","journal-title":"Disabil Rehabil"},{"issue":"2","key":"202_CR21","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1007\/s11999-011-1983-y","volume":"470","author":"SJ Kim","year":"2012","unstructured":"Kim SJ, Balce GC, Agashe MV, Song SH, Song HR (2012) Is bilateral lower limb lengthening appropriate for achondroplasia? Midterm analysis of the complications and quality of life. Clin Orthop Relat Res 470(2):616\u2013621. https:\/\/doi.org\/10.1007\/s11999-011-1983-yEpub 2011 Jul 22. PMID: 21785895; PMCID: PMC3254769","journal-title":"Clin Orthop Relat Res"},{"key":"202_CR22","volume-title":"Approval of human growth hormone for the treatment of achondroplasia","author":"Ministry of Health, Labour and Welfare (Japan)","year":"1997","unstructured":"Ministry of Health, Labour and Welfare (Japan) (1997) Approval of human growth hormone for the treatment of achondroplasia. MHLW, Tokyo"},{"issue":"1","key":"202_CR23","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1159\/000446958","volume":"86","author":"M Miccoli","year":"2016","unstructured":"Miccoli M, Bertelloni S, Massart F (2016) Height outcome of Recombinant human growth hormone treatment in achondroplasia children: A Meta-Analysis. Horm Res Paediatr 86(1):27\u201334. https:\/\/doi.org\/10.1159\/000446958Epub 2016 Jun 30. PMID: 27355624","journal-title":"Horm Res Paediatr"},{"key":"202_CR24","doi-asserted-by":"publisher","unstructured":"Tanaka N, Katsumata N, Horikawa R, Tanaka T (2003) The comparison of the effects of short-term growth hormone treatment in patients with achondroplasia and with hypochondroplasia. Endocr J. ;50(1):69\u201375. https:\/\/doi.org\/10.1507\/endocrj.50.69. PMID: 12733711","DOI":"10.1507\/endocrj.50.69"},{"key":"202_CR25","doi-asserted-by":"publisher","unstructured":"Blethen SL, MacGillivray MH (1997) A risk-benefit assessment of growth hormone use in children. Drug Saf. ;17(5):303\u2009\u2013\u200916. https:\/\/doi.org\/10.2165\/00002018-199717050-00003. PMID: 9391774","DOI":"10.2165\/00002018-199717050-00003"},{"issue":"13","key":"202_CR26","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.1056\/NEJMcp1213178","volume":"368","author":"DB Allen","year":"2013","unstructured":"Allen DB, Cuttler L (2013) Clinical practice. Short stature in childhood\u2014challenges and choices. N Engl J Med 368(13):1220\u20131228. https:\/\/doi.org\/10.1056\/NEJMcp1213178","journal-title":"N Engl J Med"},{"issue":"5","key":"202_CR27","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1016\/j.pcl.2023.05.008","volume":"70","author":"N Merchant","year":"2023","unstructured":"Merchant N, Dauber A (2023) Shedding new light: novel therapies for achondroplasia and growth disorders. Pediatr Clin North Am 70(5):951\u2013961. https:\/\/doi.org\/10.1016\/j.pcl.2023.05.008Epub 2023 Jul 6. PMID: 37704353","journal-title":"Pediatr Clin North Am"},{"issue":"3","key":"202_CR28","doi-asserted-by":"publisher","first-page":"167626","DOI":"10.1016\/j.bbadis.2024.167626","volume":"1871","author":"K Sadamori","year":"2025","unstructured":"Sadamori K, Kubo T, Yoshida T, Yamamoto M, Shibata Y, Fukasawa K, Tokumura K, Horie T, Kadota T, Yamakawa R, Hojo H, Tanaka N, Kitao T, Shirahase H, Hinoi E (2025) CDK8 inhibitor KY-065 rescues skeletal abnormalities in achondroplasia model mice. Biochim Biophys Acta Mol Basis Dis 1871(3):167626. https:\/\/doi.org\/10.1016\/j.bbadis.2024.167626Epub 2024 Dec 12. PMID: 39674288","journal-title":"Biochim Biophys Acta Mol Basis Dis"}],"container-title":["Molecular and Cellular Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40348-025-00202-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40348-025-00202-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40348-025-00202-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T13:51:22Z","timestamp":1761659482000},"score":1,"resource":{"primary":{"URL":"https:\/\/molcellped.springeropen.com\/articles\/10.1186\/s40348-025-00202-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,28]]},"references-count":28,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["202"],"URL":"https:\/\/doi.org\/10.1186\/s40348-025-00202-3","relation":{},"ISSN":["2194-7791"],"issn-type":[{"value":"2194-7791","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,28]]},"assertion":[{"value":"26 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"17"}}